Simplify Asset Management Inc. Has $3.04 Million Stock Position in Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. reduced its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 46.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,506,405 shares of the company’s stock after selling 1,326,569 shares during the quarter. Simplify Asset Management Inc. owned about 1.77% of Milestone Pharmaceuticals worth $3,043,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Strategic Family Wealth Counselors L.L.C. acquired a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth approximately $25,000. Bank of America Corp DE lifted its stake in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the period. Creative Planning lifted its stake in shares of Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after acquiring an additional 10,000 shares during the period. Bay Rivers Group lifted its stake in shares of Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after acquiring an additional 12,170 shares during the period. Finally, Raymond James Financial Inc. lifted its stake in shares of Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after acquiring an additional 10,000 shares during the period. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.41 on Monday. Milestone Pharmaceuticals Inc. has a 52-week low of $1.00 and a 52-week high of $3.06. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18. The business’s 50 day moving average price is $1.68 and its two-hundred day moving average price is $1.91. The firm has a market cap of $175.55 million, a PE ratio of -2.07 and a beta of 1.04.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. On average, equities analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.97 EPS for the current year.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 36,500 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total transaction of $82,490.00. Following the transaction, the chief executive officer directly owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wells Fargo & Company cut their price objective on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a research note on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price target on the stock. Finally, Zacks Research lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.